(3AR,7AR)-REL-叔丁基六氢-1H-吡咯并[3,4-C]吡啶-2(3H)-羧酸盐 | 1416263-25-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: (3AR,7AR)-REL-叔丁基六氢-1H-吡咯并[3,4-C]吡啶-2(3H)-羧酸盐
• 英文名称: tert-butyl (3aS,7aS)-octahydro-2H-pyrrolo[3,4-c]pyridine-2-carboxylate
• 英文别名: (3aS,7aS)-tert-butyl hexahydro-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate；tert-butyl (3aS,7aS)-1,3,3a,4,5,6,7,7a-octahydropyrrolo[3,4-c]pyridine-2-carboxylate
• CAS: 1416263-25-6
• 化学式: C₁₂H₂₂N₂O₂
• 分子量: 226.319
• InChiKey: CQJSNQCNXVJXDM-ZJUUUORDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  、 (3AR,7AR)-REL-叔丁基六氢-1H-吡咯并[3,4-C]吡啶-2(3H)-羧酸盐 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Pyrimidinopyrimidine inhibitors of ketohexokinase: Exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket

  摘要：

  Inhibitors of ketohexokinase (KHK) have potential for the treatment of diabetes and obesity. We have continued studies on a pyrimidinopyrimidine series of potent KHK inhibitors by exploring the 2-position substituent (R-3) that interacts with Asp-27B in the ATP-binding region of KHK (viz. 1, 2; Table 1). We found that increased spacing between the terminal ammonium group and the heterocyclic scaffold (viz. 16-20), such that interaction with Asp-27B is not possible, still results in potent KHK inhibition (IC50 = 15-50 nM). We propose a new interaction with Asp-194, which serves to expand the pyrimidinopyrimidine pharmacophore. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.008

文献信息

• N-ACYL CYCLIC AMINE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1061076A1

  公开（公告）日：2000-12-20

  The invention relates to compounds represented by the general formula [I] [wherein Ar means an aryl group or a heteroaryl group which may have a substitutive group selected from a group consisting of a halogen atom, a lower alkyl group and a lower alkoxy group; R1 means a C3-C6 cycloalkyl group which is substitutable with a fluorine atom; R2 and R4 mean hydrogen atoms, groups represented by -(A1)m-NH-B or the like; R3 and R5 mean hydrogen atoms, C1-C6 aliphatic hydrocarbon groups or the like which are substitutable with a lower alkyl group(s) ; n means 0 or 1; and X means an oxygen atom or a sulfur atom]. Compounds according to the invention, since they not only have potent selective antagonistic activity against muscarinic M3 receptors but also exhibit excellent oral activity, durability of action and pharmacokinetics, are very useful as safe and effective remedies against respiratory, urinary and digestive diseases with little adverse side effects.

  本发明涉及通式[I]所代表的化合物。 [其中 Ar 指芳基或杂芳基，可带有选自卤原子、低级烷基和低级烷氧基的取代基团；R1 指可被氟原子取代的 C3-C6 环烷基；R2和R4指氢原子、由-(A1)m-NH-B代表的基团或类似基团；R3和R5指氢原子、可被低级烷基取代的C1-C6脂族烃基或类似基团；n指0或1；X指氧原子或硫原子]。 根据本发明的化合物不仅对毒蕈碱类 M3 受体具有强效的选择性拮抗活性，而且具有良好的口服活性、作用持久性和药代动力学，因此非常适合作为安全有效的治疗呼吸系统、泌尿系统和消化系统疾病的药物，且不良副作用小。
• US6140333A
  申请人：——

  公开号：US6140333A

  公开（公告）日：2000-10-31
• 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF
  申请人：[en]PFIZER INC.

  公开号：WO2024127297A1

  公开（公告）日：2024-06-20

  Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide- containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Formula (II).
• WO2023/64345
  申请人：——

  公开号：——

  公开（公告）日：——
• Pyrimidinopyrimidine inhibitors of ketohexokinase: Exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket
  作者：Bruce E. Maryanoff、John C. O’Neill、David F. McComsey、Stephen C. Yabut、Diane K. Luci、Alan C. Gibbs、Margery A. Connelly

  DOI：10.1016/j.bmcl.2012.06.008

  日期：2012.8

  Inhibitors of ketohexokinase (KHK) have potential for the treatment of diabetes and obesity. We have continued studies on a pyrimidinopyrimidine series of potent KHK inhibitors by exploring the 2-position substituent (R-3) that interacts with Asp-27B in the ATP-binding region of KHK (viz. 1, 2; Table 1). We found that increased spacing between the terminal ammonium group and the heterocyclic scaffold (viz. 16-20), such that interaction with Asp-27B is not possible, still results in potent KHK inhibition (IC50 = 15-50 nM). We propose a new interaction with Asp-194, which serves to expand the pyrimidinopyrimidine pharmacophore. (C) 2012 Elsevier Ltd. All rights reserved.